Stryker saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 69 to 73.
This exclusive rating from Investor's Business Daily tracks share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
Over 100 years of market history shows that the best-performing stocks often have an 80 or higher RS Rating in the early stages of their moves. See if Stryker can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Stryker is trying to complete a flat base with a 361.41 buy point. See if it can break out in heavy trading.
While revenue growth fell last quarter from 12% to 10%, the bottom line grew 17%, up from 15% in the prior report. Look for the next report on or around Jul. 23.
The company holds the No. 10 rank among its peers in the Medical-Products industry group. LeMaitre Vascular, Globus Medical and Boston Scientific are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
